Manni Kantipudi – Chief Executive Officer - Aragen Life Sciences of Aragen
View Detailed Executive Profile →Professional Overview
- Manni Kantipudi joined Aragen Life Sciences in 2007 as President, playing a pivotal role in transforming the company into a leading provider of R&D and manufacturing solutions in the life sciences sector.
- In May 2010, Manni Kantipudi was appointed Chief Executive Officer, where responsibilities expanded to include overall growth, strategic direction, and management of mergers and acquisitions.
- Under Manni Kantipudi's leadership, Aragen Life Sciences has experienced significant growth, evolving into one of Asia's foremost discovery, development, and manufacturing organizations over a span of more than 14 years.
- Manni Kantipudi has been instrumental in steering the company’s strategic initiatives, focusing on enhancing profitability and operational efficiency while fostering innovation in product development.
- As a member of the Board of Directors at GVK BIO, Manni Kantipudi contributes to strategic decision-making and governance, further extending influence in the life sciences industry.
- With a strong emphasis on international management, Manni Kantipudi has successfully navigated the complexities of the US/India corridor, enhancing Aragen's global footprint.
- Manni Kantipudi's expertise encompasses various specialties, including general management, crisis management, and business development, which have been critical in driving the company’s success.
- Throughout the tenure, Manni Kantipudi has prioritized talent development and leadership within the organization, fostering a culture of excellence and innovation among employees.
- Strategic decisions made by Manni Kantipudi have led to successful partnerships and collaborations, enhancing Aragen's capabilities in research and development.
- Manni Kantipudi has been recognized for effective P&L management, ensuring sustainable financial health and growth for Aragen Life Sciences.
- Through a focus on outsourcing and offshoring strategies, Manni Kantipudi has optimized operational processes, resulting in increased efficiency and cost-effectiveness.
- Manni Kantipudi has played a key role in crisis management, effectively steering the organization through challenges while maintaining operational continuity.
- Under Manni Kantipudi's guidance, Aragen Life Sciences has expanded its service offerings, positioning the company as a comprehensive solutions provider in the life sciences sector.
- Manni Kantipudi's leadership has been characterized by a commitment to ethical practices and corporate responsibility, reinforcing Aragen's reputation in the industry.
- With a focus on innovation, Manni Kantipudi has championed initiatives that leverage cutting-edge technologies to enhance research capabilities and product delivery.
Professional Experience
| Company | Designation | Period |
|---|---|---|
| Aragen Life Sciences | President | May 2007 – May 2010 |
| Intel Corporation | Software Engineering Manager | May 1995 – Jun 1996 |
| Intel Corporation | Senior Manager | Jun 1996 – Jan 2000 |
| Intel Corp | Director of Intel India Development Center | Jan 2000 – Feb 2003 |
| Intel Corp | Director of EBusiness, Asia | Feb 2003 – Dec 2004 |
| Intel | Director Of Software Development | Dec 2004 – May 2007 |
| Intel Corporation | Software Engineer | Dec 1991 – May 1995 |
| YOUNG PRESIDENT'S ORGANISATION HYDERABAD CHAPTER | Director | 30-Sep-2015 – 05-Jul-2017 |
| GXP PHARMACEUTICALS PRIVATE LIMITED | Additional Director | 30-Mar-2012 – 20-Mar-2013 |
| ARAGEN LIFE SCIENCES LIMITED | Additional Director | 29-May-2018 – 04-Aug-2018 |
| YOUNG PRESIDENT'S ORGANISATION HYDERABAD CHAPTER | Additional Director | 29-Jun-2014 – 30-Sep-2015 |
| INTOX PRIVATE LIMITED | Additional Director | 25-Apr-2023 – 06-Jun-2023 |
| GXP PHARMACEUTICALS PRIVATE LIMITED | Director | 20-Mar-2013 – 29-Oct-2013 |
| INOGENT LABORATORIES PRIVATE LIMITED | Additional Director | 14-Mar-2016 – 20-Sep-2016 |
| ARAGEN LIFE SCIENCES LIMITED | Director | 04-Aug-2018 – 29-Mar-2023 |
| Aragen Life Sciences | Chief Executive Officer | May 2010 – Present |
| ARAGEN LIFE SCIENCES LIMITED | Whole-time director | 29-Mar-2023 – Present |
| INTOX PRIVATE LIMITED | Director | 26-May-2023 – Present |
| ARAGEN BIOLOGICS PRIVATE LIMITED | Director | 21-Jun-2023 – Present |
| ZEROHARM SCIENCES PRIVATE LIMITED | Director | 21-Dec-2021 – Present |
| ARAGEN FOUNDATION | Director | 21-Dec-2021 – Present |
| INOGENT LABORATORIES PRIVATE LIMITED | Director | 20-Sep-2016 – Present |
Current Appointments
| CIN/LLP | Company | Designation | Date |
|---|---|---|---|
| U21001TS2023PTC174243 | ARAGEN BIOLOGICS PRIVATE LIMITED | Director | 21-Jun-2023 |
| U24100TG2020PTC145072 | ZEROHARM SCIENCES PRIVATE LIMITED | Director | 21-Dec-2021 |
| U24239TG2005PTC046402 | INOGENT LABORATORIES PRIVATE LIMITED | Director | 20-Sep-2016 |
| U74999PN2000PTC015116 | INTOX PRIVATE LIMITED | Director | 26-May-2023 |
| U74999TG2000PLC035826 | ARAGEN LIFE SCIENCES LIMITED | Whole-time director | 29-Mar-2023 |
| U85300DL2021NPL391515 | ARAGEN FOUNDATION | Director | 21-Dec-2021 |
Previous Appointments
| CIN/LLP | Company | Designation | Period |
|---|---|---|---|
| U24239TG2005PTC046402 | INOGENT LABORATORIES PRIVATE LIMITED | Additional Director | 14-Mar-2016 – 20-Sep-2016 |
| U74999PN2000PTC015116 | INTOX PRIVATE LIMITED | Additional Director | 25-Apr-2023 – 06-Jun-2023 |
| U74999TG2000PLC035826 | ARAGEN LIFE SCIENCES LIMITED | Additional Director | 29-May-2018 – 04-Aug-2018 |
| U74999TG2000PLC035826 | ARAGEN LIFE SCIENCES LIMITED | Director | 04-Aug-2018 – 29-Mar-2023 |
| U85191PN2011PTC156428 | GXP PHARMACEUTICALS PRIVATE LIMITED | Additional Director | 30-Mar-2012 – 20-Mar-2013 |
| U85191PN2011PTC156428 | GXP PHARMACEUTICALS PRIVATE LIMITED | Director | 20-Mar-2013 – 29-Oct-2013 |
| U93000TG2007NPL055534 | YOUNG PRESIDENT'S ORGANISATION HYDERABAD CHAPTER | Additional Director | 29-Jun-2014 – 30-Sep-2015 |
| U93000TG2007NPL055534 | YOUNG PRESIDENT'S ORGANISATION HYDERABAD CHAPTER | Director | 30-Sep-2015 – 05-Jul-2017 |
Estimated Net Worth
Estimated Range: ₹0 – ₹1000+ Cr (approx. $0 – $120M+)
Based on publicly accessible filings, industry benchmarks, and leadership compensation patterns.
Executive Contact
Official Email: Via Aragen corporate communication desk.
Personal Contact: Not publicly disclosed.
Frequently Asked Questions
What is Manni Kantipudi's net worth?
Estimated ₹0 – ₹1000+ Cr (approx. $0 – $120M+).
How can I contact them?
Through Aragen's official communication channels.
Is this an official profile?
No — independently created using public data.
Disclaimer
This profile is created for general informational purposes. All details are based on publicly accessible information and independent research. While accuracy is prioritized, content may not always reflect the latest updates.
Nothing here should be interpreted as investment, financial, or legal advice. The individual featured has not authored or endorsed this profile.
Personal information is intentionally withheld. For official matters, please use formal communication channels associated with the respective organization.
Affluense AI – Smarter Insights. Stronger Relationships with Affluents.
Last Updated: December 2025 · Published by Affluense AI (affluense.ai)